Monitoring of minimal residual disease in acute myeloid leukemia
Open Access
- 13 November 2007
- Vol. 112 (1), 4-16
- https://doi.org/10.1002/cncr.23128
Abstract
Two highly sensitive methods, multiparameter flow cytometry (MFC) and real‐time quantitative PCR (RQ‐PCR), are increasingly used to monitor minimal residual disease (MRD) and to guide risk‐adapted management in acute myeloid leukemia (AML). An independent prognostic impact has been demonstrated for MRD levels obtained by both methods. MFC has been found particularly useful for assessment of early clearance of malignant cells and after consolidation therapy. At the latter checkpoint, MRD levels quantified by RQ‐PCR in AML with fusion genes also have the strongest prognostic power. In addition, highly predictive initial expression levels have been identified by RQ‐PCR. Both methods are capable of early detection of relapse. Through the use of all available markers including NPM1 mutations and FLT3 mutations in addition to fusion genes, RQ‐PCR‐based MRD assessment is possible in more than half of patients, whereas MFC is applicable to most AML cases. With a sensitivity of 10−4 (PML‐RARA) to 10−7 (patient‐specific primers, FLT3 and NPM1 mutations), RQ‐PCR is more sensitive in most cases. Large clinical trials will determine the exact role and place of immunologic and RQ‐PCR‐based monitoring of MRD in the therapy of patients with AML. Cancer 2008. © 2007 American Cancer Society.Keywords
This publication has 72 references indexed in Scilit:
- Reverse transcriptase-polymerase chain reaction based quantification of the combined MDS-EVI1/EVI1 gene in acute myeloid leukemiaLeukemia & Lymphoma, 2006
- Prognostic impact of RT-PCR-based quantification of WT1 gene expression during MRD monitoring of acute myeloid leukemiaLeukemia, 2005
- Stability of leukemia‐associated aberrant immunophenotypes in patients with acute myeloid leukemia between diagnosis and relapse: Comparison with cytomorphologic, cytogenetic, and molecular genetic findingsCytometry Part B: Clinical Cytometry, 2004
- Quantitative nested reverse transcriptase PCR vs. real-time PCR for measuring AML1/ETO (MTG8) transcriptsInternational Journal of Laboratory Hematology, 2004
- Four-fold staining including CD45 gating improves the sensitivity of multiparameter flow cytometric assessment of minimal residual diseasein patients with acute myeloid leukemiaThe Hematology Journal, 2004
- Revised Recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid LeukemiaJournal of Clinical Oncology, 2003
- Prognostic Value of Minimal Residual Disease Quantification by Real-Time Reverse Transcriptase Polymerase Chain Reaction in Patients With Core Binding Factor LeukemiasJournal of Clinical Oncology, 2003
- Pretransplant minimal residual disease level predicts clinical outcome in patients with acute myeloid leukemia receiving high-dose chemotherapy and autologous stem cell transplantationLeukemia, 2003
- Molecular monitoring of acute myeloid leukemia associated with inv(16): threshold of CBFβ/MYH11 transcript copy number above which relapse occurs and below which continuous Complete Remission is likelyLeukemia, 2003
- Detection of minimal residual disease in acute leukemia by flow cytometryCytometry, 1999